Related Experiment Videos
Erythropoietin gene expression in different areas of the developing human central nervous system
1Department of Neonatology, University Children's Hospital, Bonn, Germany.
Insights
Erythropoietin (EPO) gene is expressed throughout the developing human central nervous system (CNS). This finding supports a potential role for EPO in brain development and function.
Area of Science:
- Neuroscience
- Developmental Biology
- Molecular Biology
Background:
- Erythropoietin (EPO) is known for its neuroprotective and neurotrophic functions based on cell and animal studies.
- The distribution and expression of EPO in the developing human brain remain largely unquantified.
Purpose of the Study:
- To quantify the expression and distribution of EPO mRNA in the developing human central nervous system (CNS).
- To investigate the potential role of EPO in human brain development.
Main Methods:
- Analysis of EPO mRNA expression using competitive PCR.
- Samples obtained from postmortem examinations of four preterm fetuses (gestational age 23-37 weeks).
- Quantification in various CNS regions, kidneys, and liver.
Main Results:
- EPO mRNA was detected throughout the fetal human CNS, with highest abundance in the cerebellum and pituitary gland.
- Expression levels varied across brain regions, with higher levels in the cerebral cortex compared to the hippocampus and basal ganglia.
- EPO mRNA levels in the CNS were comparable to those found in the liver and kidneys.
Conclusions:
- The EPO gene is expressed across the fetal human CNS.
- These findings provide a foundation for exploring the function of EPO in the human brain.
Unlabelled:
Evidence from cell culture and animal experiments suggests a neuroprotective and neurotrophic function of erythropoietin (EPO). We have quantitated the distribution of EPO mRNA expression in the developing human central nervous system (CNS).
Patients And Methods:
Up to seven biopsies from different areas of the CNS of four preterm fetuses (gestational age 23-37 weeks) were obtained at routine postmortem examinations. EPO mRNA was quantitated by competitive PCR in samples from the CNS, the kidneys, and the liver where the EPO gene is predominantly expressed at this gestational age.
Results:
EPO mRNA was most abundant in one sample from the cerebellum (0.29 amol/microg total RNA [amol=10(-18)mol]) and two from the pituitary gland (0.23 amol/microg total RNA), but levels varied considerably. EPO mRNA in the cortex cerebri (median 0.12 amol/microg total RNA; n=4) dominated over the expression in the corpora amygdala (median 0.05 amol/microg total RNA; n=4), the hippocampus (median 0.03 amol/microg total RNA; n=4), or the basal ganglia (median 0.01 amol/microg total RNA; n=3). Only little EPO mRNA (<0.01 and 0.06 amol/microg total RNA) was found in the spinal cord. EPO mRNA levels in the cerebellum, pituitary gland, or the cerebral cortex were within the same range as in the liver (0.03-1.67 amol/microg total RNA; n=4), or the kidneys (0.06-0.79 amol/microg total RNA; n=4).
Conclusion:
We found the EPO gene expressed throughout the fetal human CNS. Our data provide the basis to discuss a function for EPO in the brain of humans as well.